Assorted News from the Last Week: The NCI Budget Fact Book summarizes the distribution of the fiscal year 2023 budget among the various NCI research

Assorted News from the Last Week: Lifestyle habits can alleviate the effects of cancer treatment in children. A study into precision medicine for high-risk Neuroblastoma

Assorted News from the Last Week: Congratulations to CAC2 Members Autumn Gentry (MACC Fund, Inc) and Mariah Forster Olson (Neuroblastoma Children’s Cancer Society) with inspiration

Assorted News from the Last Week: CAC2 Supporting Member Day One Biopharmaceutical and Ipsen unveiled an ex-U.S. licensing agreement for tovorafenib (approved as Ojemda in

Assorted News from the Last Week: Congratulations to CAC2 Supporting Organization Day One Biopharmaceuticals and CAC2 member authors and reviewers who contributed to the white

Assorted News from the Last Week: Psychological and ethical issues raised by genomic testing in paediatric care pathway, a qualitative analysis with parents and childhood

Assorted News from the Last Week: Building a case for incorporating patient advocates throughout the research continuum in pediatric oncology. The NCI Council of Research

Assorted News from the Last Week: AWS is providing $10 million to accelerate research for pediatric health care and to better understand rare diseases, including

Assorted News from the Last Week: CAC2 Supporting Organization Member Day One Biopharmaceuticals announced it has entered into an exclusive licensing agreement with MabCare Therapeutics

Assorted News from the Last Week: Bristol Myers Squibb’s Augtyro (repotrectinib) has secured an accelerated approval from the FDA for the treatment of adult and